NN
Nano Dimension Ltd.$NNDMRising onTrending downwardX chatter spiked vs its recent normBacked by solid revenue growth
Computer HardwareMixed sentiment
Nano Dimension signed a non-binding term sheet to merge with Infinite Epigenetics in an eight-hundred-ninety-million-dollar deal, with the combined entity intended to operate as Infinite Epigenetics and trade as IEAI with over four-hundred-million in expected cash at closing. Major shareholder Oramed Pharmaceuticals publicly opposed the transaction, having bought over eight-point-seven million in shares to boost its stake. Holders express frustration with management's strategic direction.
Broken story
Nano Dimension is an Israeli additive-electronics-printer company — DragonFly systems that print circuit boards and electronic components. The business story is now second to the M&A fight over the pending Infinite Epigenetics merger.
Where the setup nets out:
• Growth is strong: Q1 revenue up 106% YoY to $30M, and the four-quarter growth stack is 73-142% — real acceleration off a low base.
• Margins are terrible: operating margin -71% in Q1 (better than -155% in Q2), FCFy -27% — burn is severe.
• The $890M non-binding term sheet to merge with Infinite Epigenetics (with combined entity to trade as IEAI) is the M&A cloud over the equity.
• Oramed Pharmaceuticals opposes the deal — has bought $8.7M+ of shares to boost its opposition stake.
• Murchinson (activist) files continued SC 13D/A opposition — the June 23 Amendment No. 17.
• Nano Dimension board publicly defends against Murchinson's 'self-interested and destructive campaign.'
• Position: 26% of 52-week range and 13% below the 200-day moving average.
The forward view: the August 25 next earnings is a data checkpoint but the real driver is the outcome of the Infinite Epigenetics merger vote and Oramed/Murchinson opposition. What restarts the coil upward: the deal terminating and NNDM continuing standalone with improving operating margins. What keeps it stuck: continued M&A uncertainty. What breaks it lower: the merger closing at terms perceived as dilutive.